28th Mar 2018 11:13
The company expects the restructuring to lead to achieving profits earlier than expected. The annual cash cost savings from the restructuring are estimated to be
Collagen Solutions also said it will record further non-cash asset write-downs due to the restructuring which would widen the loss for the year beyond current market expectation.
The manufacturer of medical grade collagen, tissues, and related medical devices, added that it will continue to source both
The restructuring is expected to enable the company to consolidate its existing collagen production into
Shares in the company were trading 15% lower at
Related Shares:
COS.L